Atrial Fibrillation Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By End-use (Hospital, Specialty Clinics), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global atrial fibrillation market size was exhibited at USD 22.80 billion in 2023 and is projected to hit around USD 60.77 billion by 2033, growing at a CAGR of 10.3% during the forecast period of 2024 to 2033.

Key Takeaways:

• The North American region is expected to dominate the market and held the largest revenue share of over 40.% in 2023.
• The pharmacological treatment segment held the largest revenue share of over 67% of the atrial fibrillation market in 2023.
• The hospitals segment accounted for the largest share of the market in 2023, and it is estimated to register the fastest CAGR of 10.4% during the forecast period.

Atrial Fibrillation Market Report Scope

The increasing prevalence of atrial fibrillation (AFib) and growing awareness about the condition are expected to drive the market. Factors such as the aging population, lifestyle changes, and the surge in chronic illnesses such as obesity and diabetes are contributing to the rising incidence of atrial fibrillation. However, the market growth is hindered by the high costs associated with AFib procedures and devices. The COVID-19 pandemic has impacted the market by causing a decline in demand for AFib devices and procedures due to postponed non-urgent procedures. The pandemic has also led to shortages of certain medical devices and equipment due to disrupted global supply chains.

For instance, A study published in the National Library of Medicine found that cardiac surgeries in England have decreased by over 45,000 procedures during the pandemic without increasing the risk of mortality for most of these treatments. However, the pandemic has highlighted the importance of remote patient monitoring and telemedicine, which has increased during the pandemic and is expected to continue post-pandemic.

The increasing prevalence of atrial fibrillation and associated strokes is expected to drive market growth over the forecast period. In Asia, the number of atrial fibrillation cases is projected to reach 72 million by 2050, while in Europe, the number of people aged 55 and older with atrial fibrillation is expected to increase from 9 million in 2010 to 14 million by 2060. This rise in atrial fibrillation cases is driving the demand for treatments, including catheter ablation, anti-arrhythmic drugs, and non-pharmacological therapies.

Advancements in technology are transforming healthcare services and facilities for cardiovascular conditions. The rising prevalence of cardiovascular diseases is driving demand for advanced diagnostic and treatment devices that provide effective and efficient care. Key market players have successfully developed treatments for atrial fibrillation, such as in November 2021, Medtronic India launched its Arctic Front Cardiac Cryoablation Catheter System. This product targets pulmonary vein isolation to block unwanted electrical signals, enabling effective treatment of atrial fibrillation. These technological advancements and product launches are expected to fuel market growth.

Moreover, the introduction of new technologies and product approvals are increasing competition in the market. For instance, in August 2021, Abbott received the FDA's approval for its Amplatzer Amulet Left Atrial Appendage (LAA) Occluder. This product is designed to treat patients with AFib at risk of ischemic stroke, and its innovative design allows for immediately closing the LAA without the need for blood-thinning medication, effectively reducing the risk of stroke.

Segments Insights:

Treatment Type Insights

Based on treatment type, the AFib market is segmented into pharmacological and non-pharmacological treatment. The pharmacological treatment segment held the largest revenue share of over 67% of the atrial fibrillation market in 2023, due to the high demand for anticoagulant drugs and anti-arrhythmic drugs. Anticoagulant drugs held the largest share of this segment in 2023 due to these drugs are the most commonly prescribed medication for patients with atrial fibrillation. Anticoagulant drugs help prevent blood clots and reduce the risk of stroke, which is a common complication of atrial fibrillation.

The non-pharmacological segment is further segmented into catheter ablation, maze surgery, and electric cardioversion. The catheter ablation segment held the largest share of the market in 2023. Non-pharmacological techniques are becoming increasingly popular for treating atrial fibrillation and are considered the primary method for comprehensive arrhythmia management due to the limited antiarrhythmic and frequent proarrhythmic effects of drugs.

End-Use Insights

Based on end-use, the market has been further categorized into hospitals, specialty clinics, and others. The hospitals segment accounted for the largest share of the market in 2023, and it is estimated to register the fastest CAGR of 10.4% during the forecast period. The segment's rapid growth is primarily attributed to the high number of surgeries performed in hospitals, as well as the availability of skilled professionals and surgical equipment. Furthermore, the increasing prevalence of chronic disorders resulting in higher patient admissions is expected to drive the segment's growth over the forecast period.

The specialty clinics segment is also expected to gain significant growth over the forecast period owing to the increasing preference of individuals to undergo surgical interventions in specialty clinics. Moreover, the increasing prevalence of atrial fibrillation is driving demand for specialized care, and specialty clinics are well-positioned to meet this demand.

Regional Insights

The North American region is expected to dominate the market and held the largest revenue share of over 40% in 2023, owing to the increasing incidence of atrial fibrillation and a large patient population. The presence of major players in the region also contributes to this dominance. The CDC reports that in 2019, between 2.7 million and 6.1 million Americans had atrial fibrillation. By 2033, an estimated 12.1 million people in the United States will be affected by the condition. With the aging population, demand for AFib treatment is expected to increase in the coming years.

Asia Pacific is estimated to grow at the fastest rate during the forecast period. The growth is attributed to the increasing prevalence of cardiovascular diseases and atrial fibrillation in the region, coupled with investments in research and development to produce advanced cardiac care. Additionally, changing dietary habits and sedentary lifestyles are contributing to the rise in cardiovascular diseases and the demand for effective treatment options in the region.

Some of the prominent players in the Atrial fibrillation market include:

• AtriCure Inc.
• Boehringer Ingelheim GmbH
• Boston Scientific Corporation
• Bristol- Myers Squibb Corporation
• Cardio Focus Inc.
• Sanofi Aventis
• Biosense Webster Inc.
• Endoscopic Technologies Inc.
• Abbott (St. Jude Medical Inc.)
• Johnsons & Johnson

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global atrial fibrillation market.

Treatment type Scope

• Pharmacological Treatment

• • Anti-arrhythmic Drugs
  • Anticoagulant Drugs

• Non-Pharmacological Treatment

• • Catheter Ablation

• • • Radiofrequency
    • HIFU
    • Cryoablation
    • Microwave
    • Laser

• • Maze Surgery
  • Electric Cardioversion

End-Use Scope

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)